Cell And Gene Therapy Supply Chain Software Market, a rapidly growing sector, Size is valued at USD 240.5 Mn in 2023 and is predicted to reach USD 668.4 Mn by the year 2031 at a 13.9% CAGR during the forecast period for 2024-2031.
The recent commercial success of the cell and gene therapy market is to be seen due to their ability to provide the desired therapeutic benefits and developers' capacity to meet all supply chain needs efficiently. The cell & gene therapy supply chain is comparatively more complex than the conventional pharmaceutical supply chain, directing to the temperature sensitivity as well as the uniqueness of some products. As a result, there are various risks regarding process redundancy, including possible operational reluctance. Therapy developers must take care of these capacity scheduling concerns, process delays leading to capital loss, and delivery / tracking-related issues.
In recent years, the field of medicine has seen some ground-breaking developments with the emergence of Cell and Gene Therapies (CGT). CGT is rapidly altering the therapy arena, promising long-term patient maintenance or cure. To do so effectively, biopharma companies must solve the complexities of their unique supply chain. Specific supply chain capabilities are necessary to address the unique complexity of CGT products' high-touch and personalized supply chain.
The Cell & Gene Therapy Supply Chain Software market, which has experienced significant growth due to advancements in medical technology and increased demand for personalized treatments, was not immune to the effects of the COVID-19 pandemic. The pandemic disrupted the supply chain, causing delays in manufacturing, distribution, and clinical trials. This led to increased interest in supply chain software solutions to improve efficiency, visibility, and agility.
Competitive Landscape
Some of the major key players in the Cell & Gene Therapy Supply Chain Software Market are :
- Azenta Life Sciences
- Biocair
- BioLife Solutions
- CareDx
- Cryoport
- Lonza
- NMDP BioTherapies
- TraceLink
- TrakCel
- Veeva Systems
- Emerson
- LabVantage Solutions
- Marken
- MasterControl
- QuickSTAT
- Siemens
- Stafa Cellular Therapy
- Steiner
- STEMSOFT Software
- TECHNICAL
- Thermo Fisher Scientific
- Other Prominent Players
Market Segmentation:
In the cell & gene therapy supply chain software market, segmentation includes process component, type of software, mode of deployment, type of end-user, and scale of operation. The market is segmented based on process components, such as sample collection and processing components, manufacturing domains, logistics components, and patient identification and treatment follow-up components. By Type of Software, the market is segmented by enterprise manufacturing system, laboratory information management system, inventory management system, cell orchestration platform, quality management system, logistics management system, patient management system (PMS). By mode of deployment, the market is segmented by on-premises deployment, cloud-based deployment. By Type of end-user, the market is segmented by pharmaceutical companies, cell therapy labs, hospitals / medical centers, research institutes / biobanks. By Scale of operation, the market is segmented by clinical scale, commercial scale.
Based On The Process Component, The Sample Collection And Processing Component Is A Major Contributor To The Cell & Gene Therapy Supply Chain Software Market.
In the Cell & Gene Therapy Supply Chain Software Market, the Sample Collection and Processing Component is a major contributor due to its critical role in ensuring product quality and patient safety. This component involves managing the collection, transportation, and processing of biological samples in therapy production. Efficient sample management is essential for maintaining product integrity, complying with regulatory requirements, and minimizing risks of contamination or degradation. Software solutions in this area provide features for sample tracking, inventory management, chain of custody documentation, and cumulation with laboratory information management systems (LIMS), enhancing overall supply chain efficiency and reliability.
Laboratory Information Management Systems Witness Growth At A Rapid Rate.
The Laboratory Information Management System (LIMS) is experiencing rapid growth due to its pivotal role in managing complex data in laboratories. With technological enhancements and the increasing demand for precision medicine and personalized therapies, laboratories are creating vast amounts of data that require efficient organization, analysis, and storage. LIMS automates workflows, tracks samples, manages data and ensures compliance with regulations. Its ability to smoothen processes, improve data accuracy, and enhance collaboration among researchers and clinicians has fueled its adoption across various industries, including healthcare, pharmaceuticals, biotechnology, and environmental science, contributing to its rapid growth.
The North American Cell And Gene Therapy Supply Chain Software Market Holds A Significant Revenue Share In The Region.
The North America Cell and Gene Therapy Supply Chain Software Market commands a significant revenue share due to several key factors. Firstly, North America is a hub for the biotechnology and pharmaceutical industries, with a robust ecosystem of companies specializing in cell and gene therapy research, development, and manufacturing. Major cities like Boston, San Francisco, and San Diego are home to numerous biotech firms and research institutions, fostering innovation and collaboration in the field.
This can be related to the increasing R&D investments, partnership agreements, and funding gained by different therapy developers to develop novel cell and gene therapies. Moreover, the region benefits from a well-established healthcare infrastructure and regulatory framework supporting advanced therapies' development and commercialization. Concerned authorities, for instance, the Food and Drug Administration, provide clear guidelines and pathways for the approval of cell and gene therapies, instilling confidence in investors and manufacturers.
Cell & Gene Therapy Supply Chain Software Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 240.5 Mn |
|
Revenue Forecast In 2031 |
USD 668.4 Mn |
|
Growth Rate CAGR |
CAGR of 13.9% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn, and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Process Component, Type Of Software, Mode Of Deployment, Type Of End-User, And Scale Of Operation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Azenta Life Sciences, NMDP Bio-Therapies, Care DX, BioLife Solutions, Biocair, LabVantage Solutions, Lonza, TraceLink, TrakCel, Veeva Systems, Emerson, Cryoport, Marken, MasterControl, Steiner, Siemens, Stafa Cellular Therapy, QuickSTAT, STEMSOFT Software, TECHNIDATA and Thermo Fisher Scientific. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
